Repro-Med Systems, Inc. engages in the design, manufacture, and marketing of proprietary medical devices primarily for emergency medical applications and ambulatory infusion therapy worldwide. The company offers FREEDOM60 (R), a syringe infusion system that is designed for ambulatory medication infusions primarily in the home care market and hospitals. The FREEDOM60 (R) can also be used for pain control, and the infusion of specialized drugs, such as IgG and chemotherapy. It also provides Freedom60-FM, which contains an electronic flow monitor system that provides occlusion and end of infusion alarm for nursing homes, hospitals, and pediatric ambulatory applications. The Freedom60-FM can also be used for administering vancomycin, treating thalissemia with the drug desferal, pain control primarily post-operative epidural pain administration, and chemotherapy and subcutaneous immune globulin. In addition, Repro-Med Systems offers RES-Q-VAC(R) emergency airway suction system, a portable and hand-operated suction device that removes fluids from a patient's airway by attaching the RES-Q-VAC(R) pump to various proprietary sterile and non-sterile single-use catheters sized for adult and pediatric suctioning; RES-Q-VAC ULTRA, which comes with a full stop protection filter that prevents leakage and over-flow of the aspirated fluids, and traps air and fluid borne pathogens and potentially infectious materials within the sealable container; and gynecological instruments comprising Masterson Endometrial Biopsy Kit for in-office biopsy sampling procedures, and the Thermal Cautery System used for tubal ligation procedures. The company offers RES-Q-VAC(R) kits for various vertical markets comprising emergency medicine, respiratory care, hospital use, nursing homes, hospice, and dental and military applications. It sells its products through emergency medical device distributors. Repro-Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York
Web site: http://www.repro-med.com
Last updated January 30, 2012
You are attempting to access a page that requires a full Platinum Membership. Because you currently have access to and receive our Premium Alerts, we believe the ability to read why we issue our alerts is invaluable.
Our alerts reference every facet of our research:
- Premium emails
- RFT's (Reasons for Tracking)
- In-depth due diligence reports
- Spotlight research updates
- Positions Screens & Mock Portfolios
Because you have already subscribed to our Premium Alert service, we are happy to extend to you an upgrade at a very steep discount.
Just use code code TWEETUP12 to receive an 80% discount off our Annual Platinum plan, which blows away the current 60% discount we regularly offer.
And even better yet, you get one week to decide if it's right for you.
Upgrade Now and Join Thousands Who Read Our Research Every Day